Zekri Abdel-Rahman N, Hassan Zeinab K, Bahnassy Abeer A, Sherif Ghada M, ELdahshan Dina, Abouelhoda Mohamed, Ali Ahmed, Hafez Mohamed M
Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo, Egypt.
Asian Pac J Cancer Prev. 2012;13(11):5433-8. doi: 10.7314/apjcp.2012.13.11.5433.
Hepatocellular carcinoma (HCC) is a common and aggressive malignancy. Despite of the improvements in its treatment, HCC prognosis remains poor due to its recurrence after resection. This study provides complete genetic profile for Egyptian HCC. Genome-wide analyses were performed to identify the predictive signatures.
Liver tissue was collected from 31 patients with diagnosis of HCC and gene expression levels in the tumours and their adjacent non-neoplastic tissues samples were studied by analyzing changes by microarray then correlate these with the clinico-pathological parameters. Genes were validated in an independent set by qPCR. The genomic profile was associated with genetic disorders and cancer focused on gene expression, cell cycle and cell death. Molecular profile analysis revealed cell cycle progression and arrest at G2/M, but progression to mitosis; unregulated DNA damage check-points, and apoptosis.
Nine hundred fifty eight transcripts out of the 25,000 studied cDNAs were differentially expressed; 503 were up-regulated and 455 were down-regulated. A total of 19 pathways were up-regulated through 27 genes and 13 pathways were down-regulated through 19 genes. Thirty-seven genes showed significant differences in their expression between HCC cases with high and low Alpha Feto Protein (AFP≥600 IU/ml). The validation for the microarray was done by real time PCR assay in which PPP3CA, ATG-5, BACE genes showed down-regulation and ABCG2, RXRA, ELOVL2, CXR3 genes showed up-regulation. cDNA microarrays showed that among the major upregulated genes in HCC are sets.
The identified genes could provide a panel of new diagnostic and prognostic aids for HCC.
肝细胞癌(HCC)是一种常见且侵袭性强的恶性肿瘤。尽管其治疗方法有所改进,但由于切除后复发,HCC的预后仍然很差。本研究提供了埃及HCC的完整基因图谱。进行全基因组分析以识别预测性特征。
收集31例确诊为HCC患者的肝组织,通过微阵列分析肿瘤及其相邻非肿瘤组织样本中的基因表达水平变化,然后将这些变化与临床病理参数相关联。通过qPCR在独立样本中验证基因。基因组图谱与遗传疾病和癌症相关,重点关注基因表达、细胞周期和细胞死亡。分子图谱分析显示细胞周期在G2/M期进展并停滞,但可进入有丝分裂;DNA损伤检查点失控,以及细胞凋亡。
在研究的25000个cDNA中,有958个转录本差异表达;503个上调,455个下调。共有19条通路通过27个基因上调,13条通路通过19个基因下调。37个基因在高甲胎蛋白(AFP≥600 IU/ml)和低甲胎蛋白的HCC病例之间表达存在显著差异。通过实时PCR检测对微阵列进行验证,其中PPP3CA、ATG-5、BACE基因显示下调,ABCG2、RXRA、ELOVL2、CXR3基因显示上调。cDNA微阵列显示,HCC中主要上调的基因是一些基因集。
所鉴定的基因可为HCC提供一组新的诊断和预后辅助指标。